贝达药业 (300558)
Betta Pharmaceuticals Co.,Ltd
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 42073.38
- Circulating A-Shares(W): 41939.27
- Earnings Per Share(RMB): 0.7600
- Net Assets Per Share(RMB): 13.8886
- Operating Revenue(W RMB): 271734.27
- Total Profit(W RMB): 39157.40
- Net Profit Attributable to Parent(W RMB): 31693.24
- Net Profit Growth Rate(%): -23.86
- Weighted Return on Equity(%): 5.5000
- Operating Cash Flow Per Share(RMB): 1.5890
- Undistributed Profit Per Share(RMB): 6.7926
- Capital Reserve Per Share(RMB): 4.9121
2. Main Business
The main business covers:
- Production and sales of innovative drugs
3. Company Basic Information
- Company Name: Betta Pharmaceuticals Co., Ltd.
- Listing Date: 2016-11-07
- Industry: Pharmaceutical Manufacturing
- Address: No. 355 Xingzhong Road, Yuhang Economic and Technological Development Zone, Hangzhou City, Zhejiang Province
- Website: www.bettapharma.com
- Company Profile：The company was established through the overall change of Betta Limited to a joint stock company. According to the audit report issued by Lixin Certified Public Accountants on July 24, 2013, as of June 30, 2013, the audited net assets of Betta Limited were RMB 227,011,861.46. On July 30, 2013, the board of directors of Betta Limited decided that all shareholders of Betta Limited would act as promoters, converting the audited net asset value of Betta Limited as of June 30, 2013, RMB 227,011,861.46, into 150 million shares at a ratio of 1:0.6608, with a par value of RMB 1.00 per share and a registered capital of RMB 150 million. The portion of net assets exceeding the registered capital, RMB 77,011,861.46, was recorded as capital reserve. On August 20, 2013, Lixin Certified Public Accountants verified the company's registered capital and issued the capital verification report, confirming that the shareholders' contributions were in place. On August 13, 2013, the Hangzhou Foreign Trade and Economic Cooperation Bureau issued the approval document for the change of Zhejiang Betta Pharmaceutical Co., Ltd. to a joint stock company. On August 29, 2013, the company was approved for change of registration by the Hangzhou Administration for Industry and Commerce as "Betta Pharmaceuticals Co., Ltd.", with registration number 330100400024187 and registered capital of RMB 150 million.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Ningbo Kaiming Investment Management Partnership (Limited Partnership) | Legal Person | 8006.40 | 19.09 |
| 2 | Zhejiang Jihe Venture Capital Co., Ltd. | Legal Person | 5432.40 | 12.95 |
| 3 | Hangzhou Teruixichuang Enterprise Management Partnership (Limited Partnership) | Legal Person | 2879.71 | 6.87 |
| 4 | Zhejiang Beicheng Investment Management Partnership (Limited Partnership) | Legal Person | 992.46 | 2.37 |
| 5 | Xingquan Business Model Preferred Hybrid Securities Investment Fund (LOF) Class A | Fund | 582.70 | 1.39 |
| 6 | E Fund ChiNext Exchange Traded Open-End Index Securities Investment Fund | Fund | 545.55 | 1.30 |
| 7 | Xingquan Herun Hybrid Securities Investment Fund (LOF) Class A | Fund | 540.17 | 1.29 |
| 8 | New China Life Insurance Co., Ltd. - Traditional - Ordinary Insurance Product - 018LCT001 Shen | Insurance | 458.21 | 1.09 |
| 9 | Xingquan New Horizon Flexible Allocation Regular Open Hybrid Initiated Securities Investment Fund | Fund | 424.16 | 1.01 |
| 10 | Invesco Great Wall Prosperity Growth Hybrid Securities Investment Fund Class A | Fund | 171.30 | 0.41 |
5. Concept Sectors
- Gene Concept
- Immunotherapy
- Innovative Drugs
- Margin Trading & Securities Lending
- Insurance Heavy Holdings
- High-Performance Stocks
- Insurance New Entries
- ChiNext Index
- SZSE 300 Index
- Technology 100 Index
- ChiNext 300 Index
- ChiNext Innovation Index
- ChiNext Quality Index
- ChiNext Healthcare Index
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information